Searched for: in-biosketch:true
person:yannul01
Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes
D'Amico, Donald J; Goldberg, Morton F; Hudson, Henry; Jerdan, Janice A; Krueger, D Scott; Luna, Susan P; Robertson, Stella M; Russell, Stephen; Singerman, Lawrence; Slakter, Jason S; Yannuzzi, Lawrence; Zilliox, Patricia
PURPOSE: To evaluate safety and efficacy of the angiostatic agent anecortave acetate, compared with a placebo, for treatment of subfoveal choroidal neovascularization (CNV). DESIGN: Ongoing masked, randomized, placebo-controlled, parallel evaluation of anecortave acetate (30 mg, 15 mg, and 3 mg) versus a placebo. PARTICIPANTS: There were 128 eyes of 128 patients with subfoveal CNV secondary to age-related macular degeneration who were enrolled and treated, with 80% (102/128) of eyes presenting with predominantly classic lesions at baseline. METHODS: All eyes received a posterior juxtascleral depot application of masked study medication or a placebo, with retreatment at 6-month intervals if the masked investigator believed the patient could benefit. Patients received periodic detailed ophthalmic examinations with both fluorescein and indocyanine green angiography, general physical examinations with electrocardiograms, and hematology/serum chemistry/urinalysis. All ophthalmic and systemic safety data were periodically reviewed by the Independent Safety Committee overseeing the study. MAIN OUTCOME MEASURES: Best-corrected logarithm of the minimum angle of resolution (logMAR) vision and fluorescein angiographic lesion characteristics were compared over time and among treatment groups. RESULTS: At month 12, anecortave acetate (15 mg) administered at 6-month intervals was statistically superior to the placebo for 3 measures of clinical efficacy: mean change from baseline vision (P = 0.0131), stabilization of vision (<3 logMAR line change; P = 0.0323), and prevention of severe vision loss (decrease of > or = 6 logMAR lines from baseline; P = 0.0224). Subgroup analysis of predominantly classic lesions revealed that anecortave acetate (15 mg) was also superior to the placebo at 1 year for each of these 3 measures of visual outcome (Ps = 0.0022, 0.0100, and 0.0299, respectively). Anecortave acetate (15 mg) trended toward significance over the placebo at month 12 for inhibition of total lesion growth and for inhibition of both the total CNV component and the classic CNV component in both the overall and subgroup analyses. The Independent Safety Committee identified no clinically relevant treatment-related safety issues. CONCLUSIONS: Anecortave acetate (15 mg) is safe and clinically efficacious at 1 year for maintaining vision, preventing severe vision loss, and inhibiting subfoveal CNV lesion growth
PMID: 14644721
ISSN: 0161-6420
CID: 103386
Tributes to J. Donald M. Gass, M.D
Brucker, Alexander J; Yannuzzi, Lawrence A; Green, W Richard; Shields, Jerry A; Jampol, Lee M; Singerman, Lawrence J
PMID: 15035385
ISSN: 0275-004x
CID: 103426
Optical coherence tomography findings in photic maculopathy [Case Report]
Huang, Sheau Jiun; Gross, Nicole E; Costa, Danielle L L; Yannuzzi, Lawrence A
PMID: 14707841
ISSN: 0275-004x
CID: 103429
Retinal-choroidal indocyanine green dye clearance and liver dysfunction [Case Report]
Costa, Danielle L L; Huang, Sheau J; Orlock, Dennis A; Freund, K Bailey; Yannuzzi, Lawrence A; Spaide, Richard F; Gross, Nicole E
PMID: 12972775
ISSN: 0275-004x
CID: 103430
Age-dependent variations in the drusen fluorescence on indocyanine green angiography
Chang, Andrew A; Guyer, David R; Orlock, Dennis R; Yannuzzi, Lawrence A
PURPOSE: To examine the fluorescence patterns of macular drusen using indocyanine green (ICG) angiography in human subjects of different ages. METHODS: A total of 180 eyes in 100 consecutive patients aged 34-90 years with macula drusen were evaluated with ICG angiography using the Topcon 1024 ImageNet system. Eyes were divided into two groups depending on age. The older group (subjects over the age of 55 years) comprised 170 eyes. The younger group (subjects 55 years or younger) comprised 10 eyes. The fluorescence patterns of the drusen were graded as hyper-fluorescent (brighter than the background fluorescence), hypofluorescent (darker than the background fluorescence) or isofluorescent (unable to be distinguished from the background fluorescence). The ICG angiogram appearances were correlated with the clinical types of drusen in differing age groups. RESULTS: An age-dependent difference in the fluorescence pattern of drusen was observed. Drusen in the older group were hypofluorescent or isofluorescent (169/170 eyes). In contrast, drusen in the younger group (55 years or younger) were hyperfluorescent (10/10 eyes). CONCLUSIONS: This study defines the distinct age-dependent differences in the ICG fluorescence pattern of drusen. This heterogeneity might be due to differential binding of extravasated ICG to the constituents and histological site of the drusen deposits. Furthermore, ICG angiography is able to differentiate drusen types not possible by clinical and fluorescein angiographic evaluation
PMID: 12880453
ISSN: 1442-6404
CID: 103431
Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study
Yannuzzi, Lawrence A; Slakter, Jason S; Gross, Nicole E; Spaide, Richard F; Costa, Danielle L L; Huang, Sheau J; Klancnik, James M Jr; Aizman, Alexander
BACKGROUND: Most patients with central serous chorioretinopathy (CSC) have spontaneous resolution of exudative macular detachments and a good visual prognosis. Patients with CSC have a primary choroidal hyperpermeability problem evident as multifocal areas of hyperpermeability during indocyanine green (ICG) angiography. A small percentage of patients develop chronic or progressive disease with widespread decompensation of the retinal pigment epithelium and severe vision loss. There is no known treatment for this variant of the disorder. PURPOSE: To study ICG-guided photodynamic therapy (PDT) with verteporfin as a potential treatment for patients with chronic CSC. METHODS: Twenty eyes of 15 patients were studied with fluorescein angiography, optical coherence tomography, and ICG angiography to diagnose the maculopathy, monitor the detachments, and localize the choroidal hyperpermeability of the disorder. PDT with ICG guidance was applied to areas of choroidal hyperpermeability, and the patients were observed to determine the anatomic and functional outcomes. RESULTS: Photodynamic therapy guided by ICG was associated with complete resolution of exudative macular detachments in 12 patients and incomplete resolution in the remaining eight eyes. The vision improved in six eyes and remained unchanged in 14 eyes during a mean follow-up of 6.8 months. Six weeks after treatment, the mean visual acuity improved by 0.55 lines, an amount that was marginally significant. There was a significant inverse correlation between the baseline visual acuity and the amount of improvement in acuity at 6 weeks. No patient had any treatment-related side effects. CONCLUSIONS: Indocyanine green angiography-guided PDT with verteporfin seems to aid in the resolution of exudative detachments in patients with chronic CSC. This treatment was associated with a rapid reduction in subretinal fluid and improvement in visual acuity. Although the follow-up time and number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated
PMID: 12824827
ISSN: 0275-004x
CID: 65991
Peripheral drusen in membranoproliferative glomerulonephritis type II [Case Report]
Huang, Sheau Jiun; Costa, Danielle L L; Gross, Nicole E; Yannuzzi, Lawrence A
PMID: 12824858
ISSN: 0275-004x
CID: 103432
X-linked ocular albinism: fundus of a heterozygous female [Case Report]
Costa, Danielle L L; Huang, Sheau J; Donsoff, Irene M; Yannuzzi, Lawrence A
PMID: 12824848
ISSN: 0275-004x
CID: 103433
Angiographic imaging in a combined OCT/SLO prototype [Meeting Abstract]
Gross, NE; Fisher, YL; Yannuzzi, LA; Klancnik, JM; Garcia, PT; Rosen, RB
ISI:000184607000741
ISSN: 0146-0404
CID: 130286
Phenotype-genotype correlation in patients with the Goldmann-Favre syndrome [Meeting Abstract]
Klaver, CCW; Pachydaki, S; Yannuzzi, LA; Huang, SJ; Gouras, P; Allikmets, R; Barbazetto, IA
ISI:000184607002397
ISSN: 0146-0404
CID: 103701